Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William L Redmond

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|December 21, 2018
Implementation and Validation of an Automated Flow Cytometry Analysis Pipeline for Human Immune ProfilingValerie K Conrad, Christopher J Dubay, Mehrnoush Malek, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 10, 2004
B7-2 (CD86) controls the priming of autoreactive CD4 T cell response against pancreatic isletsDeepak Yadav, Valeria Judkowski, Malin Flodstrom-Tullberg, et al.
Journal for Immunotherapy of Cancer|April 21, 2022
Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8<sup>+</sup> T cell cytotoxicity over BEMPEG+RTAnnah S Rolig, Daniel C Rose, Grace Helen McGee, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 6, 2016
Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing miceStefanie N Linch, Melissa J Kasiewicz, Michael J McNamara, et al.
Cancer Immunology Research|June 5, 2016
Interferon-γ Production by Peripheral Lymphocytes Predicts Survival of Tumor-Bearing Mice Receiving Dual PD-1/CTLA-4 BlockadeMichael J McNamara, Ian Hilgart-Martiszus, Diego M Barragan Echenique, et al.
The Analyst|August 23, 2022
A rapid and universal liquid chromatograph-mass spectrometry-based platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeuticsNoriko Iwamoto, Yoshinobu Koguchi, Kotoko Yokoyama, et al.
Journal for Immunotherapy of Cancer|October 8, 2021
Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumabYoshinobu Koguchi, Noriko Iwamoto, Takashi Shimada, et al.
European Journal of Cancer (Oxford, England : 1990)|June 18, 2017
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscapeLeisha A Emens, Paolo A Ascierto, Phillip K Darcy, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 2005
CD8+ T cell tolerance in nonobese diabetic mice is restored by insulin-dependent diabetes resistance allelesXavier Martinez, Huub T C Kreuwel, William L Redmond, et al.
Oncoimmunology|March 15, 2021
Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunityElizabeth R Sturgill, Annah S Rolig, Stefanie N Linch, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|December 21, 2018
Implementation and Validation of an Automated Flow Cytometry Analysis Pipeline for Human Immune ProfilingValerie K Conrad, Christopher J Dubay, Mehrnoush Malek, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 10, 2004
B7-2 (CD86) controls the priming of autoreactive CD4 T cell response against pancreatic isletsDeepak Yadav, Valeria Judkowski, Malin Flodstrom-Tullberg, et al.
Journal for Immunotherapy of Cancer|April 21, 2022
Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8<sup>+</sup> T cell cytotoxicity over BEMPEG+RTAnnah S Rolig, Daniel C Rose, Grace Helen McGee, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 6, 2016
Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing miceStefanie N Linch, Melissa J Kasiewicz, Michael J McNamara, et al.
Cancer Immunology Research|June 5, 2016
Interferon-γ Production by Peripheral Lymphocytes Predicts Survival of Tumor-Bearing Mice Receiving Dual PD-1/CTLA-4 BlockadeMichael J McNamara, Ian Hilgart-Martiszus, Diego M Barragan Echenique, et al.
The Analyst|August 23, 2022
A rapid and universal liquid chromatograph-mass spectrometry-based platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeuticsNoriko Iwamoto, Yoshinobu Koguchi, Kotoko Yokoyama, et al.
Journal for Immunotherapy of Cancer|October 8, 2021
Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumabYoshinobu Koguchi, Noriko Iwamoto, Takashi Shimada, et al.
European Journal of Cancer (Oxford, England : 1990)|June 18, 2017
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscapeLeisha A Emens, Paolo A Ascierto, Phillip K Darcy, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 2005
CD8+ T cell tolerance in nonobese diabetic mice is restored by insulin-dependent diabetes resistance allelesXavier Martinez, Huub T C Kreuwel, William L Redmond, et al.
Oncoimmunology|March 15, 2021
Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunityElizabeth R Sturgill, Annah S Rolig, Stefanie N Linch, et al.
Pageof 7